Lv21
170 积分 2024-02-06 加入
Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry
2小时前
待确认
Pembrolizumab plus enfortumab vedotin in urothelial cancer
19天前
已完结
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
20天前
已完结
Overcoming tumour resistance in cancer immunotherapy through predictive and pharmacodynamic biomarkers
21天前
已完结
Exploring the next generation of antibody–drug conjugates
1个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
1个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
2个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells
2个月前
已完结
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer
2个月前
已完结
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor
4个月前
已完结
皖公网安备34019202002308
